- Long-term efficacy analysis confirms the potential clinical benefit in lung cancer patients with squamous cell…
Continue ReadingTag: molmed-s-p-a
The European Patent Office Grants MolMed a New Patent on Its Anticancer Drug NGR-hTNF
MILAN, ITALY -- (Marketwire) -- 06/18/12 -- MolMed S.p.A. (MILAN: MLM) announces today that it received…
Continue ReadingMolMed: New Phase II Data on Investigational Drug NGR-hTNF Presented at ASCO
First data of a randomised 1st-line study indicate an extension of survival in squamous cell lung…
Continue ReadingMolMed S.p.A.: Update on TK Clinical Benefit Presented at ASH and Expansion of Phase III Trial in Europe
MILAN, ITALY -- (Marketwire) -- 12/12/11 -- MolMed S.p.A. (MILAN: MLM) presented at ASH an update…
Continue Reading